# US 2026/0294981 A1 · Cryopreserved endocrine cells that express chromogranin a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0294981 A1
- Document ID: US20260294981A1
- Status: Published application
- Kind: A1
- Application number: 19/571,087
- Filed: 2026-03-18
- Published: 2026-10-01
- Earliest claimed: 2013-03-14
- Assignees: ViaCyte, Inc.
- Applicants: ViaCyte, Inc.
- Inventors: Alan D. Agulnick; Kevin Allen D'Amour
- Web page: https://patentgrep.com/patent/US20260294981A1

## CPC

- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C12N 5/0676: {Pancreatic cells}
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/117: Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/195: Heregulin, neu differentiation factor
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

## Claims

### Claim 1

An in vitro cell culture of human cells comprising PDX1+ and NKX6.1+ pancreatic progenitor cells and INS+ cells; and further comprising:
a) an effective amount of retinoic acid or retinoic acid analogue, wherein the effective amount is sufficient to promote differentiation of the PDX1+ and NKX6.1+ pancreatic progenitor cells into INS+ cells; and
b) an effective amount of a rho kinase inhibitor and/or a gamma secretase inhibitor, wherein the effective amount is sufficient to promote differentiation of the PDX1+ and NKX6.1+ pancreatic progenitor cells into INS+ cells.

### Claim 2 (depends on 1)

The in vitro cell culture of claim 1, comprising the effective amount of retinoic acid.

### Claim 3 (depends on 1)

The in vitro cell culture of claim 1, comprising the effective amount of the retinoic acid analogue, wherein the retinoic acid analogue is 4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB).

### Claim 4 (depends on 1)

The in vitro cell culture of claim 1, comprising the rho kinase inhibitor, wherein the rho kinase inhibitor is Y-27632, Fasudil (HA1077), H-1152P, Wf-536, or Y-30141.

### Claim 5 (depends on 1)

The in vitro cell culture of claim 1, comprising the rho kinase inhibitor, wherein the rho kinase inhibitor is Y-27632.

### Claim 6 (depends on 1)

The in vitro cell culture of claim 1, comprising the gamma secretase inhibitor, wherein the gamma secretase inhibitor is RO4929097, Z-Leu-Leu-Norleucine-CHO, gamma secretase inhibitor II (GSI II), N-Benzyloxycarbonyl-Leu-leucinal, N-(2-Naphthoyl)-Val-phenylalaninal, N-Benzyloxycarbonyl-Leu-phenylalaninal, 1-(S)-endo-N-(1,3,3)-Trimethylbicyclo[2.2.1]hept-2-yl)-4-fluorophenyl Sulfonamide, Menthyloxycarbonyl-LL-CHO, N—[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester, {1S-Benzyl-4R-[1-(1S-carbamoyl-2-phenethylcarbamoyl)-1S-3-methylbutylcarbamoyl]-2R-hydroxy-5-phenylpentyl}carbamic Acid tert-butyl Ester, 7-Amino-4-chloro-3-methoxyisocoumarin, Z-Ile-Leu-CHO, Z-Tyr-Ile-Leu-CHO, Z-Cys(t-Bu)-Ile-Leu-CHO, N—[N-3,5-Difluorophenacetyl]-L-alanyl-S-phenylglycine methyl ester, WPE-III-31C, (2S,3R)-3-(3,4-Difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-butyramide, (S,S)-2-[2-(3,5-Difluorophenyl)acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propionamide, (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide, S-3-[N′-(3,5-difluorophenyl-alpha-hydroxyacetyl)-L-alanilyl]amino-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one, (N)—[(S)-2-hydroxy-3-methyl-butyryl]-1-(L-alaninyl)-(S)-1-amino-3-methyl-4,5,6,7-tetrahydro-2H-3-benzazepin-2-one, BMS-708163, LY450139, MK-0752, LY-411575, LY2811376, N-trans-3,5-Dimethoxycinnamoyl-Ile-leucinal, N-tert-Butyloxycarbonyl-Gly-Val-Valinal, and Isovaleryl-V-V-Sta-A-Sta-OC3.

### Claim 7 (depends on 1)

The in vitro cell culture of claim 1, comprising the gamma secretase inhibitor, wherein the gamma secretase inhibitor is (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide.

### Claim 8 (depends on 1)

The in vitro cell culture of claim 1, comprising both the rho kinase inhibitor and the gamma secretase inhibitor.

### Claim 9 (depends on 8)

The in vitro cell culture of claim 8, wherein the rho kinase inhibitor is a Y-27632 and the gamma secretase inhibitor is (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide.

### Claim 10 (depends on 1)

The in vitro cell culture of claim 1, further comprising betacellulin.

### Claim 11 (depends on 1)

The in vitro cell culture of claim 1, further comprising a hedgehog inhibitor.

### Claim 12 (depends on 11)

The in vitro cell culture of claim 11, wherein the hedgehog inhibitor is a sonic hedgehog inhibitor.

### Claim 13 (depends on 1)

The in vitro cell culture of claim 1, further comprising biotin.

### Claim 14 (depends on 1)

The in vitro cell culture of claim 1, wherein the human cells are genetically recombinant.

### Claim 15 (depends on 1)

The in vitro cell culture of claim 1, encapsulated in a semipermeable encapsulation device.

### Claim 16 (depends on 1)

The in vitro cell culture of claim 1, wherein the in vitro cell culture is cryopreserved.
